Peter Rothschild

Peter Rothschild

Chairman of the Board since 2011. Born 1950.

Master of Business Administration from Stockholm School of Economics.
Chairman of the Board of Directors of TriPac AB, TwoPac Aktiebolag, TwoPac Machine AB, Looft Industries AB, CapAble AB, TwoPac Laboratories AB, MetaboGen AB, Atina Enterprises AB, Nefor Holding AB and Voranco Holding AB. Member of the Board of Directors of Annwall & Rothschild Investments AB, the Allbright Foundation and Founder and President of the BioGaia group.
Previously CEO of BioGaia AB (publ), member of the Board of Directors of Moberg Pharma AB and the Institution of Biology and Biochemistry at Chalmers University.
Shareholding in the Company: 222 198 series A shares and 241 458 series B shares through Annwall & Rothschild Investments AB, a company co-owned with Jan Annwall.
Non-independent in relation to the Company, its management and in relation to major shareholders.
Jan Annwall

Jan Annwall

Board member since 2014. Born 1950.

Business Administration degree from Stockholm University.
Member of the Board of Directors and CEO of Annwall & Rothschild Investments AB and Konglomeratet AB. Deputy member of the Board of Directors of Looft Industries AB. Founder and Board Member of BioGaia AB (publ).
Previously member of the Board of Directors of TwoPac Aktiebolag, TwoPac Machine AB, TwoPac Laboratories AB, TriPac AB and CapAble AB. Executive Vice President and CFO of BioGaia.
Shareholding in the Company: 222 198 series A shares and 241 458 series B shares through Annwall & Rothschild Investments AB, a company co- owned with Peter Rothschild.
Non-independent in relation to major shareholders but independent in relation to the Company and its management.
Anders Ekblom

Anders Ekblom

Board member since 2014. Born 1954.

M.D., Ph.D, D.D.S and Associate Professor at Karolinska Institutet.
Chairman of the Board of Directors of Karolinska University Hospital and TFS International AB. Member of the Board of Directors of the Swedish Research Council, Mereo Biopharma Ltd., Medivir Aktiebolag, AnaMar AB, RSPR Pharma AB, and NxtScience AB.
Previously member of the Board of Directors and CEO of AstraZeneca AB, and chairman, member or deputy member of the Board of Directors of a number of subsidiaries of AstraZeneca AB. Member of the Board of Directors of Albireo AB, SwedenBIO Service AB and Viscogel AB.
Shareholding in the Company: 27 519 series B shares through the wholly-owned company NxtScience AB.
Independent in relation to the Company, its management and in relation to major shareholders.
Margareta Hagman

Margareta Hagman

Board member since 2015. Born 1966.

Master of Business Administration, Örebro University.
Deputy CEO of BioGaia. Member of the Board of Directors of TwoPac Machine AB, TwoPac Laboratories AB and CapAble AB, TwoPac Aktiebolag, TriPac AB and Annwall & Rothschild Investments AB.
Shareholding in the Company: 2 100 series B shares.
Independent in relation to the Company and its management but not in relation to major shareholders.
Anthon Jahreshog

Anthon Jahreshog

Board member since 2017. Born 1980.

MSc Financial Management.
Anthon is former Chief Operating Officer, Fund Linked Products, Credit Suisse Investment Bank, London. Anthon is currently working as a business strategist and advisor in various industries.
Anthon is a member of the Board of Directors of BioGaia AB (publ) and Board Member of SparkHub Ltd. Furthermore, Anthon is owner and member of the Board of Directors of Hamilton Park Consulting Ltd.
Shareholding in the company: none
Independent of the company and its management and in relation to major shareholders.
Eva Idén

Eva Idén

Board member since 2017. Born 1966.

Eva has a Degree in Chemical Engineering from Chalmers University of Technology. She has extensive experience from leading management positions in Astra and AstraZeneca.
Eva is currently a consultant in leadership and organizational development, and is the business owner of Better & Beyond AB and a partner in Inflecto AB. Eva Idén is on the board of Better & Beyond AB.
Shareholding in the company: 30 series B shares.
Independent in relation to the Company and its management and in relation to major shareholders.